Antag Therapeutics

We are excited to announce that Antag Therapeutics has closed an €80 million Series A financing round, led by Versant Ventures with participation from existing investors Novo Holdings, Longview Ventures, and Export and Investment Fund of Denmark, as well as new investors SR One Capital Management, Dawn Biopharma, Pictet Asset Management. 🎉 This funding will accelerate the clinical development of our lead candidate, AT-7687, a novel, once-weekly subcutaneous antagonist of the Glucose-Dependent Insulinotropic Polypeptide Receptor (#GIPR), targeting obesity management. It will also fuel the expansion of our pipeline of monthly injectable therapies. Preclinical studies of AT-7687 in combination with a GLP-1 receptor agonist have demonstrated the potential to deliver industry leading weight loss alongside significant metabolic benefits. With FDA clearance of our #IND application, we are thrilled to initiate Phase I clinical trials early next year, evaluating AT-7687 as both a monotherapy and in combination with a GLP-1 receptor agonist in obese patients. A huge thank you to our investors for their trust and support in helping us take this important step forward in delivering novel #obesity treatments! Read the full press release on our website, linked in the comments below. #Biotech #GIPRAntagonist #GIP #AntagTherapeutics #Financing

📢 @Antag Therapeutics is pleased to announce #FDA IND clearance for AT-7687, our lead molecule for the treatment of #obesity.   AT-7687 is a peptide GIP receptor antagonist, designed for once-weekly subcutaneous administration. Preclinical studies have demonstrated that AT-7687 attenuates weight gain and enhances GLP-1-mediated weight loss while also improving lipid profiles, particularly LDL, independently of weight changes.   Our phase I clinical trial will evaluate the safety, tolerability, and pharmacokinetics of AT-7687, both as a monotherapy and in combination with #semaglutide, in healthy lean and healthy obese participants.   This is a significant milestone for #AntagTherapeutics, and we look forward to updating you as we progress AT-7687 through clinical development.   Read the full press release, linked in the comments below.   #clinicalupdate #INDclearance #GIP

🌍 Obesity remains a major global health challenge, affecting over 1 billion people worldwide, with projections that more than half of the population will be affected by 2035. While GLP-1-based therapies have made significant strides in treating obesity, their limitations highlight the urgent need for more advanced solutions.   📢 I'm excited to share a recent publication validating Antag’s novel approach to tackling obesity. Our in vivo proof-of-concept study, published in Molecular Metabolism, showcases the promising results of our lead candidate, AT-7687, a GIPR peptide antagonist, combined with the GLP-1 agonist liraglutide. This combination therapy demonstrated significant weight reduction, improved metabolic and cardiovascular results, and was well tolerated.   At Antag, we're pioneering new approaches in obesity treatment and are eager to advance AT-7687 into clinical trials soon. This milestone brings us closer to delivering a more tolerable and effective solution for obesity management.   #Obesity #InnovationInHealthcare #GLP1 #GIPR #Antagonism #Antagtherapeutics #Biotech https://lnkd.in/db5bEs4a

🌍 Obesity remains a major global health challenge, affecting over 1 billion people worldwide, with projections that more than half of the population will be affected by 2035. While GLP-1-based therapies have made significant strides in treating obesity, their limitations highlight the urgent need for more advanced solutions.   📢 I'm excited to share a recent publication validating Antag’s novel approach to tackling obesity. Our in vivo proof-of-concept study, published in Molecular Metabolism, showcases the promising results of our lead candidate, AT-7687, a GIPR peptide antagonist, combined with the GLP-1 agonist liraglutide. This combination therapy demonstrated significant weight reduction, improved metabolic and cardiovascular results, and was well tolerated.   At Antag, we're pioneering new approaches in obesity treatment and are eager to advance AT-7687 into clinical trials soon. This milestone brings us closer to delivering a more tolerable and effective solution for obesity management.   #Obesity #InnovationInHealthcare #GLP1 #GIPR #Antagonism #Antagtherapeutics #Biotech https://lnkd.in/db5bEs4a